Bexsero Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to outbreaks of meningococcal disease, pediatric vaccination initiatives, regulatory approvals for group b vaccines, public health awareness, government procurement programs.

The growth in the forecast period can be attributed to expansion of adolescent vaccination, increased public health funding, improved vaccine coverage, outbreak preparedness strategies, global immunization initiatives. Major trends in the forecast period include expansion of meningococcal vaccination programs, increased focus on pediatric immunization, government led public health campaigns, rising awareness of invasive meningococcal disease, integration into national immunization schedules.

The rising prevalence of meningitis is expected to drive the growth of the bexsero market going forward. Meningitis is the inflammation of the protective membranes surrounding the brain and spinal cord, typically caused by an infection. The increasing prevalence of meningitis can be attributed to factors such as higher infection rates, changes in vaccination coverage, weakened immunity, and improved detection and reporting systems. Bexsero protects against meningitis by stimulating the immune system to produce antibodies specifically targeting Neisseria meningitidis group B bacteria, thereby reducing the risk of invasive meningococcal disease, which can cause life-threatening inflammation of the brain and spinal cord membranes. For example, in August 2024, the UK Health Security Agency (UKHSA) reported that the meningococcal reference unit confirmed 378 cases of invasive meningococcal disease (IMD) in 2024-25, up from 341 cases in 2023-24. Consequently, the rising prevalence of meningitis is contributing to the growth of the bexsero market.

The growth of the bexsero market is also supported by increasing research and development activities. R&D involves systematic exploration and development of new knowledge, products, or technologies through research and experimentation. Rising R&D activities are driven by the demand for innovative solutions to address emerging health threats and improve treatment efficacy. R&D benefits Bexsero by optimizing its formulation, enhancing its efficacy and safety, and enabling its use across broader populations and emerging meningococcal strains. For example, in July 2025, Eurostat, a Luxembourg-based statistical agency, reported that total government budget allocations for R&D across the EU reached an estimated €127.91 billion in 2024, a 3.4% increase from €123.67 billion in 2023. Therefore, the growing research and development activities are contributing to the expansion of the bexsero market.

Leading companies in the bexsero market are focusing on developing advanced solutions, such as meningococcal B vaccines, to expand protection against multiple strains within serogroup B. These vaccines are designed to prevent infections caused by Neisseria meningitidis serogroup B, the bacterium responsible for invasive meningococcal disease, including meningitis and bloodstream infections. For instance, in July 2024, GlaxoSmithKline (GSK) Plc, a UK-based pharmaceutical company, launched the Bexsero vaccine in South Korea. The vaccine contains four key recombinant proteins - NHBA, NadA, fHbp, and the outer membrane vesicle PorA P1.4 - selected based on a complete genetic analysis of meningococcal B. This formulation induces the production of bactericidal antibodies targeting multiple mechanisms of meningococcal B antigens.

Major companies operating in the bexsero market are GlaxoSmithKline plc.

North America was the largest region in the bexsero market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bexsero market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bexsero market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the bexsero market by increasing costs related to vaccine manufacturing components and cold chain distribution systems. These effects are most visible in public immunization programs across europe and asia pacific. Higher import duties have influenced government vaccine procurement budgets. Logistics and delivery timelines have also been affected by regulatory requirements. However, tariffs are supporting domestic vaccine production and strengthening national immunization supply chains.

The bexsero market research report is one of a series of new reports that provides bexsero market statistics, including bexsero industry global market size, regional shares, competitors with a bexsero market share, detailed bexsero market segments, market trends and opportunities, and any further data you may need to thrive in the bexsero industry. This bexsero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bexsero is a meningococcal group B vaccine developed to prevent invasive meningococcal disease caused by Neisseria meningitidis group B. It is indicated for active immunization in individuals aged 2 months and older, offering protection against meningitis and septicemia caused by this bacterial strain.

The main bexsero formulations include injectable suspensions and pre-filled syringes. An injectable suspension is a liquid preparation containing finely divided drug particles suspended in a liquid medium, intended for injection. It is distributed through hospitals, pharmacies, and public health programs, and is used by adults, elderly patients, adolescents, and children.

The bexsero market consists of sales of meningococcal vaccines, pneumococcal vaccines, hepatitis vaccines, influenza vaccines and travel vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.